A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review
English
2016
African Journal of Pharmacy and Pharmacology
English
Despite advances in the research on new antifungal agents, Amphotericin B (AmB) is still considered as the antifungal of choice for treating most systemic mycoses due to its potency and broad-spectrum action. However, this drug has limited use because of its toxic effects on kidneys, liver and blood. The search for new and safe formulations of AmB is essential because of the emergence of antifungal resistance to other drugs and the increased number of immunosuppressed patients. Nanoparticles
doi:10.5897/ajpp2015.4280
fatcat:7kjoyjtlcrf2dhep2brffvudxu